Semaglutide Eligibility Dallas-Fort Worth TX: BMI, Health Checks & Qualifiers

BMI Requirements for Semaglutide in Dallas-Fort Worth

Semaglutide for weight management (branded Wegovy) is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher in the presence of at least one weight-related comorbidity [1]. These are the same criteria applied by DFW clinics prescribing both branded and compounded semaglutide as of March 2026. There is no Texas-specific BMI override — federal FDA labeling governs eligibility.

BMI is calculated from height and weight: weight in kilograms divided by height in meters squared (kg/m²). For practical purposes, a 5’6” adult weighing 186 lbs has a BMI of approximately 30.0, the minimum for the primary obesity indication. A 5’10” adult needs to weigh at least 209 lbs to reach BMI 30 [2].

Dallas County's adult obesity rate stands at 35.2% as of the most recent CDC PLACES data, meaning approximately 1 in 3 Dallas County adults qualify on BMI alone [3]. Across the broader DFW metroplex, Tarrant County's obesity rate is 34.8% and Collin County's is 27.9%, reflecting the north DFW suburban health gradient where wealthier Collin County communities have lower obesity prevalence. However, even at Collin County's lower rate, a substantial share of adults qualify through the BMI 27+ comorbidity pathway [3].

The table below shows BMI ranges, their clinical classification, and semaglutide qualification status.

Based on FDA-approved Wegovy prescribing information (NDA 215256) and standard clinical application at DFW weight-loss clinics as of March 2026 [1].

One practical note for DFW patients: BMI is measured at your clinic visit, not self-reported. If your BMI is borderline (27.0 to 27.5 without a confirmed comorbidity, or 29.8 to 30.2), bring documentation of any weight-related health conditions to your first appointment. Some clinics will use the comorbidity pathway if your BMI is marginally below 30, while others require strict BMI 30+ without exception. Ask the clinic's policy before scheduling [4].

For patients with severe obesity (BMI 40+), semaglutide is clinically appropriate but DFW bariatric surgeons at practices like DFW Bariatrics and General Surgery may recommend discussing both medical and surgical weight-loss pathways at your initial visit. Semaglutide and bariatric surgery are not mutually exclusive — some patients use GLP-1 agonists pre-operatively to reduce surgical risk [4].

Qualifying Comorbidities for Semaglutide at BMI 27–29.9

If your BMI falls between 27.0 and 29.9, you need at least one weight-related comorbidity to qualify for semaglutide. The FDA's approved label for Wegovy specifies four qualifying comorbidities, and most DFW clinics follow the same framework [1]. Some providers apply expanded clinical judgment for additional conditions; those are noted below. Always have your physician confirm whether your specific diagnosis qualifies under your clinic's prescribing policy.

Hypertension (high blood pressure). Hypertension is defined as systolic blood pressure consistently at or above 130 mmHg or diastolic at or above 80 mmHg, or current use of antihypertensive medications [5]. It is the most common qualifying comorbidity among DFW patients seeking semaglutide, reflecting Texas's hypertension prevalence of 32.4% in adults [3]. Even mild hypertension controlled by medication counts — the comorbidity does not need to be uncontrolled to qualify. Bring your most recent blood pressure reading or medication list to your appointment.

Type 2 diabetes (T2D). Type 2 diabetes qualifies both as an eligibility comorbidity and, when present, opens a separate clinical pathway: Ozempic (semaglutide 0.5 to 2.0 mg) is FDA-approved specifically for glycemic control in T2D, which is covered more broadly by Texas insurance plans than Wegovy [1][6]. If you have T2D and obesity, discuss with your provider whether Wegovy (weight management) or Ozempic (diabetes) is the more appropriate and cost-effective prescription for your situation. Many DFW internal medicine clinics, including KDI Health in Frisco and Hope Internal Medicine in Plano, specialize in this dual-indication population [4].

Dyslipidemia. Dyslipidemia — abnormal blood lipid levels including high LDL cholesterol, low HDL cholesterol, or elevated triglycerides — is a qualifying comorbidity [1]. A diagnosis requires a lipid panel showing levels outside normal ranges or current use of lipid-lowering therapy (statins, fibrates, niacin). Dyslipidemia affects approximately 38% of Texas adults, making it the second most common qualifying comorbidity in the DFW patient population [3]. Bring lab results or a current medication list showing statin or lipid therapy.

Obstructive sleep apnea (OSA). Obstructive sleep apnea is a qualifying comorbidity, and it is clinically significant because semaglutide has demonstrated improvements in apnea-hypopnea index in clinical trials [1]. A formal OSA diagnosis requires a sleep study (polysomnography or home sleep test). If you use a CPAP machine, you almost certainly have a documented OSA diagnosis that qualifies. Informal self-reported snoring alone does not qualify without a clinical diagnosis.

Non-alcoholic fatty liver disease (NAFLD) and PCOS. These two conditions are not in the FDA's approved label but are commonly accepted by DFW clinics applying expanded clinical criteria. NAFLD affects an estimated 25-30% of DFW adults and is directly worsened by obesity; some providers accept a documented NAFLD diagnosis from a gastroenterologist or hepatologist as a qualifying condition [5]. Polycystic ovary syndrome (PCOS) is accepted at several DFW women's health clinics, including Women's Wellness Institute of Dallas, given the strong association between insulin resistance, weight gain, and PCOS. Confirm whether your specific clinic accepts these conditions before your appointment [4].

Absolute Contraindications: Hard Disqualifiers for Semaglutide

Absolute contraindications are conditions under which semaglutide must not be prescribed, regardless of BMI, weight-loss need, or clinical circumstance. These are not gray areas subject to physician discretion — they are FDA-mandated boxed warnings and labeled contraindications. If you have any of the following, no legitimate DFW clinic will prescribe semaglutide, and you should not pursue it [1].

Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies showing dose-dependent thyroid tumors with GLP-1 receptor agonist exposure. While the clinical significance in humans has not been confirmed, the FDA requires contraindication labeling for anyone with a personal or family history of MTC. This applies to all GLP-1 agonists, not just semaglutide. If you have MTC anywhere in your first-degree family history (parents, siblings, children), disclose this at your first appointment. A responsible DFW provider will not prescribe semaglutide in this scenario [1].

Multiple Endocrine Neoplasia syndrome type 2 (MEN2). MEN2 is a hereditary syndrome involving MTC, pheochromocytoma, and hyperparathyroidism. Because MTC is a component of MEN2, semaglutide is absolutely contraindicated in any patient with a MEN2 diagnosis or suspected MEN2 based on family history. Genetic testing for MEN2 (RET proto-oncogene mutations) is available through UT Southwestern and Baylor Scott & White in the DFW area if you have a family history concern [5].

Pregnancy. Semaglutide is contraindicated during pregnancy (Pregnancy Category X equivalent under new labeling). Animal studies have shown embryo-fetal toxicity and structural abnormalities. Women of childbearing age who are considering semaglutide should use effective contraception throughout treatment. If you become pregnant while on semaglutide, discontinue immediately and contact your provider. The Novo Nordisk pregnancy registry (1-800-727-6500) tracks outcomes for patients exposed during pregnancy [1].

Breastfeeding. It is not known whether semaglutide is excreted in human milk. Because the potential for serious adverse reactions in nursing infants exists, breastfeeding is contraindicated during semaglutide treatment. Patients who are breastfeeding should wait until they have fully weaned before starting treatment [1].

Known hypersensitivity to semaglutide. A prior serious hypersensitivity reaction (anaphylaxis, angioedema) to semaglutide or any component of the formulation is an absolute contraindication. This is rare in first-time patients but would disqualify anyone who has reacted to a previous GLP-1 agonist prescription [1].

Relative Contraindications: Conditions Requiring Physician Evaluation

Relative contraindications are conditions that increase risk or require careful clinical evaluation before starting semaglutide. They do not automatically disqualify you, but they require honest disclosure and physician judgment. DFW providers at practices with physician oversight (internal medicine, bariatric medicine) are better equipped to evaluate these than med spas with NP-only staffing. Be direct about these conditions at your initial consultation [1][5].

Gallbladder disease or history of gallstones. GLP-1 receptor agonists reduce gallbladder motility, which can promote gallstone formation and increase the risk of cholecystitis (gallbladder inflammation) and cholelithiasis (gallstones). Clinical trials of Wegovy showed a higher rate of gallbladder-related events compared to placebo. If you have a history of gallstones, active gallbladder disease, or are at high risk (female, over 40, recent rapid weight loss), your provider should assess your gallbladder status before prescribing. Patients who have had a cholecystectomy can generally proceed, as gallbladder risk is eliminated [1].

History of pancreatitis. There have been post-marketing reports of acute pancreatitis in patients using GLP-1 agonists, though a causal relationship has not been established. Patients with a history of pancreatitis should discuss the risk-benefit balance with their physician before starting semaglutide. Active pancreatitis is a reason to discontinue treatment. Symptoms to watch for include severe abdominal pain radiating to the back, which should prompt immediate discontinuation and emergency evaluation [1].

Severe gastrointestinal disease. Gastroparesis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), or other severe GI conditions may be exacerbated by semaglutide, which significantly slows gastric emptying. Patients with these conditions require careful evaluation and may need dose adjustments or alternative approaches. Nausea and vomiting, the most common semaglutide side effects, are more clinically significant for patients with pre-existing GI disease [1].

Diabetic retinopathy. The SUSTAIN-6 trial found a higher rate of diabetic retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring surgery) in patients treated with semaglutide compared to placebo, primarily in patients with pre-existing retinopathy. Rapid A1C lowering is thought to be the mechanism. Patients with a diagnosis of diabetic retinopathy should have an ophthalmology evaluation before starting semaglutide and should be monitored during treatment [1].

Depression, suicidal ideation, or serious psychiatric conditions. The FDA requires monitoring for depression, mood changes, and suicidal ideation in patients treated with weight-loss medications. While a causal link between GLP-1 agonists and psychiatric adverse events has not been established, patients with active or recently active depression, bipolar disorder, or a history of suicidal ideation should be evaluated by both their prescribing provider and their mental health provider before starting treatment. Disclose your psychiatric history fully [1][5].

Self-Assessment Checklist Before Your DFW Clinic Visit

This checklist helps you organize the information your DFW provider needs to assess your eligibility. It is not a substitute for clinical evaluation — your provider makes the final determination. Check each item before your first appointment to ensure your visit is efficient and thorough.

BMI Check

What to know: Your current height and weight. Calculate your BMI at cdc.gov/bmi or ask at check-in.
You likely qualify if: BMI 30 or higher. You may qualify with comorbidity if BMI is 27.0 to 29.9.
Bring: No documentation required — the clinic will measure. However, knowing your number in advance helps set expectations.

Comorbidity Check (if BMI 27–29.9)

What to know: Whether you have been diagnosed with hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea.
You qualify via this pathway if: You have at least one of these diagnoses documented by a prior provider.
Bring: Your current medication list (statins, antihypertensives, diabetes medications, CPAP prescription) or a copy of a recent lab showing elevated A1C or lipids.

Absolute Contraindication Check

What to disclose: Any personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Any family history of MTC (parents, siblings, children). Current pregnancy or breastfeeding. Prior anaphylaxis or angioedema to a GLP-1 medication.
If yes to any: Do not proceed with semaglutide. Consult your physician about alternative weight-loss approaches.
Bring: Family medical history documentation if you have a thyroid cancer family history.

Relative Contraindication Check

What to disclose: History of gallstones or gallbladder disease. History of pancreatitis. Gastroparesis, Crohn's disease, or ulcerative colitis. Diabetic retinopathy. Current or recent treatment for depression, anxiety, or suicidal ideation.
If yes to any: Disclose fully at your appointment. Your provider will evaluate whether semaglutide is appropriate, may order additional workup, or may consult your specialist before prescribing.
Bring: Records or specialist names for any of the above conditions.

Medication Interaction Check

What to know: Semaglutide slows gastric emptying and can affect the absorption of oral medications taken with meals, including oral contraceptives, thyroid medications (levothyroxine), and diabetes medications.
Potential interactions: Insulin and insulin secretagogues (sulfonylureas) used with semaglutide increase hypoglycemia risk significantly; your diabetes medication dosages may need adjustment.
Bring: A complete, current medication list including all prescriptions, over-the-counter medications, and supplements. Do not omit anything — let your provider evaluate interactions.

Completing this checklist before your appointment reduces the likelihood of a wasted visit, unexpected disqualification, or missed contraindications. The most common reason DFW patients leave their first appointment without a prescription is failure to bring medication lists or lab documentation that would have supported their comorbidity eligibility [4].

What to Expect at Your First DFW Semaglutide Appointment

Your first appointment at a DFW weight-loss clinic is a clinical eligibility evaluation, not just a prescription pickup. What happens at that visit depends on whether the clinic is an internal medicine practice, a med spa, or a telehealth provider — but the core elements are consistent across legitimate providers. Here is what to expect and how to prepare [4].

Lab Work

Most DFW clinics require baseline labs before prescribing. The standard panel includes a comprehensive metabolic panel (CMP), which covers kidney and liver function; hemoglobin A1C to screen for undiagnosed diabetes or prediabetes; and thyroid-stimulating hormone (TSH) to rule out thyroid disease that could affect weight or interact with treatment. Some clinics — particularly internal medicine practices like Lone Star Medical Associates in Plano and Hope Internal Medicine — also order a complete blood count (CBC) and lipid panel [4].

Labs cost $50 to $150 out-of-pocket at most DFW clinics if not covered by insurance. Turnaround is typically 1 to 3 business days, which means your prescribing visit may be split across two appointments: one to draw labs and one to review results and initiate treatment. Some clinics use in-office rapid labs for key values (A1C, TSH) that return results within 20 to 30 minutes, allowing same-day prescribing. Ask the clinic what their lab protocol is when scheduling.

Physical Exam and Medical History

Your provider will measure your height, weight, and blood pressure at the visit. This confirms your BMI and establishes baseline vital signs. A focused medical history review covers prior weight-loss attempts, current medications, relevant diagnoses, family history (specifically thyroid cancer and MEN2), and any symptoms suggesting contraindicated conditions. At internal medicine clinics, a brief physical exam may also be performed. Med spas and aesthetics practices typically do less comprehensive physical exams than physician-led internal medicine practices; if you have complex medical history, a physician-supervised practice is more appropriate [4].

Insurance and Prior Authorization Discussion

If you intend to use insurance for branded Wegovy, your first appointment is also when prior authorization documentation begins. Your provider's office needs to document your BMI, qualifying comorbidities, and previous weight-loss attempts to submit the prior authorization to your carrier. BCBS Texas and UnitedHealthcare require 5 to 10 business days for prior authorization approval; Cigna takes up to 15 business days [6]. Some DFW clinics assist with the prior authorization process as part of their fee — Elixir 360 Health in Southlake and Lone Star Medical Associates in Plano explicitly offer this service [4]. If you are paying cash for compounded semaglutide, prior authorization is not needed.

Walk-In vs. Referral Requirements

Access model varies significantly across DFW clinics. Walk-in appointments (no referral required, same-week availability) are offered at Q Day Walk-In Clinic in Plano, InjectCo in Dallas, and most med spas across Frisco, Southlake, and Dallas. Internal medicine practices — including Hope Internal Medicine in Plano and KDI Health in Frisco — generally require an appointment but accept self-referred patients without a primary care referral. DFW Bariatrics and General Surgery in Dallas requires a referral or prior bariatric consultation for their semaglutide program. If you want the fastest path to your first injection, med spas and walk-in clinics are the fastest entry point; if you have complex comorbidities, physician-supervised internal medicine practices provide more comprehensive evaluation [4].

Starting Your First Dose

Semaglutide follows a dose escalation schedule to minimize GI side effects. The starting dose is 0.25 mg subcutaneously once weekly for 4 weeks, followed by dose increases every 4 weeks (0.5 mg, 1.0 mg, 1.7 mg, then the maintenance dose of 2.4 mg for Wegovy). Most DFW clinics teach self-injection technique at the first visit or via instructional video. The first injection can be given the same day as your qualifying appointment at most DFW practices, provided labs do not reveal a disqualifying finding [1][4].

Texas-Specific Eligibility Notes

Texas follows federal FDA eligibility criteria without additional state-specific BMI thresholds. However, several Texas Medical Board (TMB) rules affect how DFW providers prescribe semaglutide, particularly for telehealth and out-of-state prescribers.

Texas Medical Board and the prescriber relationship. The Texas Medical Board requires that all prescriptions originate from a valid physician-patient or provider-patient relationship established through clinical evaluation [7]. For telehealth providers, this means a synchronous (live video) consultation is required before prescribing — platforms that issue prescriptions based solely on asynchronous questionnaires (you fill out a form, no live contact) are not in compliance with Texas Medical Board rules. If you receive a semaglutide prescription from an online platform without any live interaction with a licensed provider, that prescription is not issued in accordance with Texas law [7].

Age restrictions. Semaglutide (Wegovy) is FDA-approved for chronic weight management in adults (18 and older) and for adolescents aged 12 and older when used under a pediatrician's supervision. In practice, DFW weight-loss clinics restrict prescribing to adults 18 and older. Pediatric obesity management in Texas requires a pediatrician or pediatric endocrinologist, not a standard adult weight-loss clinic [1].

Telehealth prescribing and cross-state licensing. Texas requires telehealth providers prescribing to Texas patients to hold a Texas medical license or a Texas telehealth exemption. Out-of-state platforms that prescribe compounded semaglutide to DFW patients without a Texas-licensed provider in the prescribing chain are operating outside TMB guidelines. If your prescription comes from a platform based in another state, verify that a Texas-licensed provider is part of the prescribing process [7].

No Texas Medicaid coverage for weight loss. Texas Medicaid does not cover GLP-1 agonists for obesity management as of March 2026. Eligibility criteria are met for the medication; coverage is the separate barrier [6].

Semaglutide Eligibility FAQ